Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET
Company Participants
Sonia Weigle - SVP, IR, HR, and Corporate Affairs
Scott Braunstein - Chairman and CEO
Christy Shafer - CCO
Joseph Hulihan - CMO
Steven E. Pfanstiel - CFO and COO
Conference Call Participants
Brian Abrahams - RBC Capital Markets
Joseph Thome - TD Cowen
Andrew Tsai - Jefferies
Charles Duncan - Cantor Fitzgerald
Joon Lee - Truist Securities
Marc Goodman - Leerink Partners
Douglas Tsao - H.C. Wainwright
Jay Olson - Oppenheimer
Operator
Greetings and welcome to the Marinus Pharmaceuticals’ Second Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. And now it is my pleasure to introduce you to your host, Sonya Weigle, Senior Vice President Investor Relations, Human Resources, and Corporate Affairs. You may now begin Ms. Weigle.
Sonia Weigle
Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the Securities Laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the Company’s reports filed with the Securities and Exchange Commission including Form 10-K, 10-Q and 8-K. I will now turn the call over to our CEO, Scott Braunstein.
Scott Braunstein
Thank you, Sonia and welcome to our call. We've made strong progress this quarter on both the regulatory and commercial front, as well as advancing our oral and IV ganaxolone clinical programs positioning us well for the catalyst rich year ahead. We are pleased to report ZTALMY’s second quarter sales of $4.2 million. The launch momentum has continued and as a result, we are raising for year 2023 ZTALMY sales guidance in the range of $17 million to $18.5 million. Christy Shafer, our Chief Commercial Officer will be reviewing some of the key initiatives for 2023 that we believe will support the continued long-term growth of the ZTALMY franchise.